Otsuka Pharmaceutical Co.
Food Company and Pharmaceutical Company
Earnings Preview: Bristol-Myers 3Q earnings report...Abilify in the U.S. for a new use, irritability in kids with autism. The company says it is still pursuing licensing and other deals, and it is awaiting approval of belatacept, for prevention of rejection of kidney transplants, next spring. In this article: Bristol-Myers, Plavix, Revenue, Abilify, Food and Drug Administration, AstraZeneca PLC, Bristol, Ipilimumab, and Otsuka Pharmaceutical Co. |
-
www.otsuka.com
2007年3月29日
Egypt Otsuka Pharmaceutical Co., S.A.E. Nutrition & Santé SAS ... Autism/Tablet. US. Filed. Schizophrenia/Depot injection. US、EU. Phase III. Bipolar disorder/Tablet ...
-
finance.yahoo.com
U.S. Food and Drug Administration Approves ABILIFY ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) and Otsuka Pharmaceutical Co., Ltd. ... for autism-linked irritability ...
-
www.otsuka-us.com
Welcome to Otsuka America Pharmaceutical, Inc.
Otsuka supports the local Autism Walk event to raise money to continue research ... OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. 0109W-0602 ...
-
www.smartbrief.com
Otsuka Pharmaceutical Co., Ltd. Profile
... Health Care > FDLI SmartBrief > Otsuka Pharmaceutical Co., Ltd. Profile ... for the treatment of irritability associated with autistic disorder in pediatric ...
-
www.biospace.com
FDA Approves Bristol-Myers Squibb Company , Otsuka ...
... LA, Daniels J, Giarelli E, et al. The epidemiology of autism spectrum disorders. ... Otsuka Pharmaceutical Co., Ltd. • Food and Drug Administration (FDA) ...
-
www.business.com
Squibb Corporation Information | Business.com
... Profile, Research) and Otsuka Pharmaceutical Co's anti-psychotic drug Abilify to ... for child autism irritability Reuters adsrc 'reuters.co.uk/finance ...
-
www.bioportfolio.co.uk
Biotechnology News ABILIFY Search
... Meyers' Abilify to treat irritability linked to autism in children, teens ... Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. ...
-
www.medscape.com
Autism Medication Found to be Ineffectual in Treatment of ...
... and Company; Neuropharm Group plc; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc. ... Otsuka Pharmaceutical Co., Ltd., Pfizer Inc.; sanofi-aventis; Sepracor Inc. ...
-
www.examiner.com
Otsuka America Pharmaceutical, Inc. Announces the Appointment ...
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer, ... autism ... Otsuka Pharmaceutical Co. ...
Trends
Loading...
More on Otsuka Pharmaceutical Co.
Description from Wikipedia:
Otsuka Pharmaceutical Co., Ltd., abbreviated OPC, is a pharmaceutical company headquartered in Tokyo, Osaka and Naruto, Japan. The company was established August 10, 1964, and currently has approximately 27,000 employees worldwide. The company focuses on pharmaceuticals related to nutrition (or "Nutraceuticals"). The company is also known for the popular sports drink Pocari Sweat and the best-selling energy drink Oronamin C. Otsuka Pharmaceutical also developed Abilify (aripiprazole), an approved drug treatment for schizophrenia and bipolar disorder, which they claim has a better side-effect profile compared with other antipsychotic drugs. The annual sales of this drug are approximately $2 billion a year, as of 2007.
Explore everything named Otsuka Pharmaceutical Co....
